SCHEMBL9221

SCHEMBL9221

O=Cc1ccc(B(O)O)o1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.47
TSHR P16473 1/20 0.47
GAA P10253 1/20 0.42
KDM4E B2RXH2 8/20 0.39
TDP1 Q9NUW8 2/20 0.39
POLB P06746 5/20 0.38
L3MBTL1 Q9Y468 3/20 0.38
LMNA P02545 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
HTT P42858 1/20 0.38
CYP2E1 P05181 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2D6 P10635 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2B6 P20813 1/20 0.34
CYP2C19 P33261 1/20 0.34
LDHA P00338 1/20 0.34
LDHB P07195 1/20 0.34
HAO1 Q9UJM8 1/20 0.34
HPGD P15428 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9960823 1.00 ALDH1A1 (0.47) ALDH1A1TSHRGAAKDM4ETDP1
Furan SCHEMBL17140223 0.89 ALDH1A1 (0.39) ALDH1A1TSHRGAAKDM4ETDP1
SCHEMBL9946109 0.77 GAA (0.47) ALDH1A1TSHRGAAKDM4ETDP1
SCHEMBL31236254 0.76 KDM4E (0.36) ALDH1A1TSHRGAAKDM4ETDP1
SCHEMBL51391 0.74
SCHEMBL18187371 0.74 KDM4E (0.42) TSHRKDM4ETDP1
SCHEMBL28571795 0.72 ALDH1A1 (0.54) ALDH1A1TSHRGAAKDM4ETDP1
SCHEMBL28562313 0.72 ALDH1A1 (0.54) ALDH1A1TSHRGAAKDM4ETDP1
SCHEMBL28565958 0.72 ALDH1A1 (0.54) ALDH1A1TSHRGAAKDM4ETDP1
SCHEMBL28576319 0.72 ALDH1A1 (0.54) ALDH1A1TSHRGAAKDM4ETDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1063 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250194617-A1 Materials and Methods for Extending Shelf-Life of Foods JP LABORATORIES, INC. 2025-06-19 US claimed
US-20250169514-A1 Materials and Methods for Extending Shelf-Life of Foods JP LABORATORIES, INC. 2025-05-29 US claimed
CN-119702022-A Boron-phosphorus co-doped carbon-based solid acid catalyst with strong adsorptivity, and preparation method and application thereof 中国科学院宁波材料技术与工程研究所 2025-03-28 CN claimed
CN-118271090-B Method for improving isostatic graphite and isostatic graphite prepared by same 湖南德智新材料有限公司 2024-07-26 CN claimed
CN-118344394-A Near infrared fluorescent probe with large Stokes displacement hydrogen peroxide based on ICT mechanism and preparation method and application thereof 青岛科技大学 2024-07-16 CN claimed
CN-118271090-A Method for improving isostatic graphite and isostatic graphite prepared by same 湖南德智新材料有限公司 2024-07-02 CN claimed
CN-117946084-A Linear aza D-A type nonlinear optical material, and preparation method and application thereof 浙江工业大学 2024-04-30 CN claimed
US-20230380457-A1 Materials and Methods for Extending Shelf-Life of Foods JP LABORATORIES, INC. 2023-11-30 US claimed
EP-4280882-A2 MATERIALS AND METHODS FOR EXTENDING SHELF-LIFE OF FOODS JP LABORATORIES, INC. (US) 2023-11-29 EP claimed
US-20230363426-A1 Materials and Methods for Extending Shelf-Life of Foods JP LABORATORIES, INC. 2023-11-16 US claimed
US-20100197915-A1 LAPATINIB INTERMEDIATES TEVA PHARMACEUTICALS USA, INC. 2010-08-05 US claimed
WO-2010061400-A1 A NOVEL PROCESS FOR THE PREPARATION OF LAPATINIB AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS NATCO PHARMA LIMITED (IN) 2010-06-03 WO claimed
US-20100040538-A1 Polymer Systems for Lung Volume Reduction Therapy CANADIAN IMPERIAL BANK OF COMMERCE (CA) 2010-02-18 US claimed
WO-2010017387-A2 LAPATINIB INTERMEDIATES TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2010-02-11 WO claimed
EP-2059227-A2 POLYMER SYSTEMS FOR LUNG VOLUME REDUCTION THERAPY Aeris Therapeutics, Inc. (US) 2009-05-20 EP claimed
WO-2008039827-A2 POLYMER SYSTEMS FOR LUNG VOLUME REDUCTION THERAPY AERIS THERAPEUTICS, INC. (US) 2008-04-03 WO claimed
US-7045640-B2 Method of producing 5-formyl-2-furylboronic acid DEGUSSA AG (DE) 2006-05-16 US claimed
EP-1403271-B1 Method of producing 5-formyl-2-furylboronic acid DEGUSSA (DE) 2005-11-16 EP claimed
US-20040127725-A1 Method of producing 5-formyl-2-furylboronic acid DEGUSSA AG (DE) 2004-07-01 US claimed
EP-1403271-A1 Method of producing 5-formyl-2-furylboronic acid Degussa AG (DE) 2004-03-31 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197915-A1 LAPATINIB INTERMEDIATES ERBB2, ABL1, EGFR ALDH1A1 2645/4885TSHR 1966/4885GAA 1410/4885
US-20100040538-A1 Polymer Systems for Lung Volume Reduction Therapy GFER, MUC1, CTH ALDH1A1 1749/4885TSHR 411/4885GAA 2727/4885
US-20040127725-A1 Method of producing 5-formyl-2-furylboronic acid FPR2, FPR1, FPR3 ALDH1A1 860/4885TSHR 2348/4885GAA 3773/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.